David R Whitmire

US Patent:

6369078, Apr 9, 2002

Filed:

Aug 29, 2000

Appl. No.:

09/650257

Inventors:

J. Phillip Bowen - Hull GA 30646
M. Scott Furness - Montgomery Village MD 20886
David Whitmire - Watkinsville GA 30677

International Classification:

A61K 31445

US Classification:

514315, 514317, 546184, 546248

Abstract:

The present invention relates to solenopsin alkaloid derivatives which are trans-2,6-disubstituted piperidines according to the structure: wherein R and R are selected from a C to C saturated or unsaturated linear, cyclic or branch-chained substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted aromatic group, or an ester group. In certain preferred embodiments, where R or R contains an unsaturated group, such as an alkenyl group, the double bond in the alkenyl group preferably is found in the hydrocarbon chain between the carbon atom bonded to the piperidine ring and the adjacent carbon atom ( and carbons).

US Patent:

8168657, May 1, 2012

Filed:

Jan 24, 2003

Appl. No.:

10/502080

Inventors:

J. Phillip Bowen - Hull GA, US
Jack L. Arbiser - Atlanta GA, US
David Whitmire - Atlanta GA, US
M. Scott Furness - Bethesda MD, US

International Classification:

A61K 31/445

US Classification:

514315

Abstract:

The present invention relates to solenopsin A and its analogs for use as angiogenesis inhibitors. The present compounds unexpectedly exhibit good activity as angiogenesis inhibitors, which find use as antitumor/anticancer agents as well as to treat a number of conditions or disease states in which angiogenesis is a factor.

US Patent:

57595399, Jun 2, 1998

Filed:

Jun 6, 1995

Appl. No.:

8/470738

Inventors:

David R. Whitmire - Watkinsville GA

Assignee:

Georgia Research Foundation, Inc. - Athens GA

International Classification:

A61K 3844

US Classification:

424 943

Abstract:

A method and formulations have been developed to accelerate ethanol elimination from the body, which combine enzymes that oxidize alcohol to acetate, enzymes which regenerate NADH to NAD, substrates which are rate limiting for the requisite enzymes, buffering agents which protect the enzymes against pH variations (e. g. low gastric pH), gastric acid sequestrants which block synthesis of gastric acid, protease inhibiting agents and other agents which protect the enzymes against proteolysis, carbohydrates which protect labile enzymes against bile salt inactivation, and a source of oxygen for efficient catalysis by some of the enzymes, with a packaging for delivery of a functional enzyme system to an appropriate in vivo site for ethanol conversion to acetate. The oxygen source can be mechanical means, such as a tube or catheter which directs oxygen from a high pressure source into the upper gastrointestinal tract for the most rapid removal of ethanol from the blood as in the case where a patient has overdosed and is unconscious, a physical carrier of oxygen, for example, oxygen microencapsulated in an appropriate polymeric matrix, or an oxygen generating formulation such as catalase (one to ten million units) with hydrogen peroxide (0. 1-200 grams), which is stable to passage through the stomach and releases oxygen in the gastrointestinal tract.

US Patent:

61158178, Sep 5, 2000

Filed:

May 6, 1998

Appl. No.:

9/072986

Inventors:

David R. Whitmire - Watkinsville GA

International Classification:

H04L 900

US Classification:

713171

Abstract:

In accordance with the present invention, methods and systems consistent with the present invention facilitate the transmission of secure messages across an insecure network. The sender requests a recipient's security software object by, for example, clicking on a button or icon on the recipient's web page. A security software object with encapsulated security information and routing information is transmitted to the sender. The sender composes a message using the security software object. When sender indicates completion, the security software object secures the message according to the security procedure of the object and transmits the secured message to the recipient.

US Patent:

6120806, Sep 19, 2000

Filed:

Jun 25, 1997

Appl. No.:

8/882176

Inventors:

David R. Whitmire - Watkinsville GA

International Classification:

A61K 916
A61K 4732
A61P 2532

US Classification:

424497

Abstract:

An oral controlled release dosage form for cyanamide whereby a portion of a cyanamide dose administered to a patient remains transiently partitioned within encapsulating material, thereby retarding metabolism of the total administered cyanamide dose, is described. No investigator has reported the use of dosage forms enabling controlled release of cyanamide. The preparation, when administered to ethanol metabolizing individuals, can elevate blood acetaldehyde to such levels, and for such periods of time, that the individuals will be deterred from future alcohol consumption. The controlled release of cyanamide provides an optimal time-profile of alcohol deterrence specific for individual patients. The formulation avoids the side-effects associated with the relatively high concentrations of cyanamide and cyanamide-metabolites, and the attendant untoward toxic effects, caused by a typical bolus cyanamide dose, thereby attenuating the intensity of the sickness caused by acetaldehyde, and increasing patient compliance with cyanamide therapy.